What is Neumora Therapeutics Inc's earnings per share (EPS)?

Neumora Therapeutics Inc (NMRA) reported diluted earnings per share of $-1.45 for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neumora Therapeutics Inc Financials

NMRA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Neumora Therapeutics Inc (NMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NMRA FY2025 2026-05-07

Cash runway, not reported earnings, is the governing mechanic as R&D-heavy spending consumes a mostly cash asset base.

FY2025 looked leaner on the expense lines, with R&D down to $176M from $201M. Yet operating cash outflow still worsened to -$206M from -$183M, so program funding needs are still overwhelming the savings visible in reported expenses and cash conversion has not improved.

With $183M of cash against $191M of total assets in FY2025, the balance sheet is essentially a cash reservoir rather than an operating asset base. R&D of $176M versus depreciation of just $208K shows a capital-light research model where money is consumed by scientific work and personnel, not by maintaining heavy physical infrastructure.

Cash fell to $183M in FY2025 from $374M in FY2023, shrinking the amount of spending the company can self-fund from prior capital raises and making runway a more immediate balance-sheet question. At the same time, long-term debt moved from $0 to $55M, showing the financing mix is broadening because operations still do not replenish cash.

Financial Health Signals

Financial Profile 49/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Neumora Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Neumora Therapeutics Inc carries a low D/E ratio of 0.53, meaning only $0.53 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.87, Neumora Therapeutics Inc holds $5.87 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

100

Neumora Therapeutics Inc earns a strong 228.1% return on equity (ROE), meaning it generates $228 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 84.9% the prior year.

Piotroski F-Score Weak

2/9

Neumora Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

-0.87x

For every $1 of reported earnings, Neumora Therapeutics Inc generates $-0.87 in operating cash flow (-$206.4M OCF vs $236.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-120.0x

Neumora Therapeutics Inc earns $-120.0 in operating income for every $1 of interest expense (-$241.2M vs $2.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$240.9M

YoY+8.3%

Neumora Therapeutics Inc's EBITDA was -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.3% from the prior year.

Net Income

$236.9M

YoY-2.8%

Neumora Therapeutics Inc reported $236.9M in net income in fiscal year 2025. This represents a decrease of 2.8% from the prior year.

EPS (Diluted)

$-1.45

YoY+5.2%

Neumora Therapeutics Inc earned $-1.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$182.5M

YoY+28.4%

Neumora Therapeutics Inc held $182.5M in cash against $54.5M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

174M

YoY+7.8%

Neumora Therapeutics Inc had 174M shares outstanding in fiscal year 2025. This represents an increase of 7.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

228.1%

YoY+143.2pp

Neumora Therapeutics Inc's ROE was 228.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 143.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$176.1M

YoY-12.4%

Neumora Therapeutics Inc invested $176.1M in research and development in fiscal year 2025. This represents a decrease of 12.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

NMRA Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$176.1M-12.4%	$200.9M+40.8%	$142.7M+55.6%	$91.7M
SG&A Expenses	$60.1M-3.9%	$62.5M+37.5%	$45.5M+46.1%	$31.1M
Operating Income	-$241.2M+8.5%	-$263.5M-4.5%	-$252.1M-85.5%	-$135.9M
Interest Expense	$2.0M	$0	N/A	N/A
Income Tax	$130K-27.0%	$178K-33.6%	$268K	N/A
Net Income	$236.9M-2.8%	$243.8M+203.3%	-$235.9M-80.2%	-$130.9M
EPS (Diluted)	$-1.45+5.2%	$-1.53+57.9%	$-3.63	$-4.81

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$38.6M	N/A	$40.5M+4.6%	$38.7M-25.7%	$52.2M	N/A	$60.6M+24.7%	$48.6M
SG&A Expenses	$14.3M	N/A	$12.2M-20.5%	$15.3M-18.5%	$18.8M	N/A	$16.0M+5.4%	$15.2M
Operating Income	-$52.9M	N/A	-$57.7M-6.8%	-$54.0M+23.8%	-$70.9M	N/A	-$76.6M-20.1%	-$63.8M
Interest Expense	$1.4M	N/A	$747K	N/A	$0	N/A	$0	N/A
Income Tax	$30K	N/A	$0-100.0%	$25K-76.2%	$105K	N/A	$53K-57.6%	$125K
Net Income	-$53.5M	N/A	-$56.8M-7.6%	-$52.7M+22.4%	-$68.0M	N/A	-$72.5M-23.6%	-$58.7M
EPS (Diluted)	$-0.30	N/A	$-0.35-6.1%	$-0.33+21.4%	$-0.42	N/A	$-0.45-21.6%	$-0.37

NMRA Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$191.0M-39.7%	$317.0M-36.1%	$496.2M+16.4%	$426.2M
Current Assets	$190.5M-39.3%	$314.1M-34.3%	$478.3M+23.3%	$388.0M
Cash & Equivalents	$182.5M+28.4%	$142.1M-62.0%	$374.0M+55.2%	$240.9M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$87.2M+191.5%	$29.9M+10.3%	$27.1M-96.9%	$873.1M
Current Liabilities	$32.5M+8.6%	$29.9M+19.0%	$25.1M+6.0%	$23.7M
Long-Term Debt	$54.5M	$0	N/A	N/A
Total Equity	$103.9M-63.8%	$287.1M-38.8%	$469.1M+205.0%	-$446.9M
Retained Earnings	-$1.2B-25.0%	-$947.2M-34.7%	-$703.4M-50.5%	-$467.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$153.9M-19.5%	$191.0M+7.4%	$177.8M-20.5%	$223.8M-12.8%	$256.7M-19.0%	$317.0M-10.1%	$352.5M-12.8%	$404.5M
Current Assets	$153.4M-19.5%	$190.5M+7.6%	$177.1M-20.6%	$222.9M-12.5%	$254.9M-18.8%	$314.1M-9.9%	$348.6M-12.5%	$398.3M
Cash & Equivalents	$147.1M-19.4%	$182.5M+41.4%	$129.1M+3.7%	$124.5M-1.8%	$126.9M-10.8%	$142.1M-48.4%	$275.7M+83.0%	$150.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$83.2M-4.6%	$87.2M+90.9%	$45.7M+11.5%	$40.9M+44.3%	$28.4M-5.1%	$29.9M-5.9%	$31.8M+37.0%	$23.2M
Current Liabilities	$30.1M-7.2%	$32.5M+25.6%	$25.8M+22.1%	$21.2M-25.5%	$28.4M-5.0%	$29.9M-5.9%	$31.7M+37.3%	$23.1M
Long-Term Debt	$53.0M-2.9%	$54.5M+178.8%	$19.6M+0.6%	$19.5M	N/A	$0	N/A	N/A
Total Equity	$70.7M-32.0%	$103.9M-21.4%	$132.2M-27.7%	$182.9M-19.9%	$228.4M-20.4%	$287.1M-10.5%	$320.7M-15.9%	$381.3M
Retained Earnings	-$1.2B-4.5%	-$1.2B-5.3%	-$1.1B-5.3%	-$1.1B-5.2%	-$1.0B-7.2%	-$947.2M-6.6%	-$888.4M-8.9%	-$815.9M

NMRA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$206.4M-12.8%	-$182.9M-12.0%	-$163.3M-42.1%	-$114.9M
Capital Expenditures	N/A	N/A	$117K-77.1%	$511K
Free Cash Flow	N/A	N/A	-$163.4M-41.6%	-$115.4M
Investing Cash Flow	$168.5M+338.8%	-$70.6M-209.6%	$64.4M+138.3%	-$168.0M
Financing Cash Flow	$77.1M+256.8%	$21.6M-90.7%	$231.9M+100.4%	$115.7M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$46.4M+3.2%	-$48.0M-2.8%	-$46.6M+11.0%	-$52.4M+11.8%	-$59.4M-18.1%	-$50.3M-50.3%	-$33.5M+40.4%	-$56.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$71K-99.8%	$42.6M-16.9%	$51.3M+68.8%	$30.4M-31.2%	$44.2M+144.7%	-$98.8M-162.9%	$157.0M+638.6%	$21.3M
Financing Cash Flow	$10.9M-81.5%	$58.8M+43311.8%	-$136K-100.7%	$18.5M	$0-100.0%	$15.6M+917.2%	$1.5M-42.3%	$2.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NMRA Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	228.1%+143.2pp	84.9%+135.2pp	-50.3%	N/A
Return on Assets	124.0%+47.1pp	76.9%+124.5pp	-47.5%-16.8pp	-30.7%
Current Ratio	5.87-4.6	10.51-8.5	19.05+2.7	16.37
Debt-to-Equity	0.53+0.5	0.00-0.1	0.06+2.0	-1.95
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-75.6%	N/A	-42.9%-14.1pp	-28.8%+0.9pp	-29.8%	N/A	-22.6%-7.2pp	-15.4%
Return on Assets	-34.7%	N/A	-31.9%-8.3pp	-23.6%+2.9pp	-26.5%	N/A	-20.6%-6.1pp	-14.5%
Current Ratio	5.09-0.8	5.87-1.0	6.85-3.7	10.54+1.6	8.98-1.5	10.51-0.5	10.98-6.2	17.22
Debt-to-Equity	0.75+0.2	0.53+0.4	0.15+0.0	0.11-0.0	0.12+0.1	0.00-0.1	0.10+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Annexon, Inc. ANNX

$812.7M

Tonix Pharmaceut TNXP

$227.3M

Vanda Pharma VNDA

$365.6M

Candel Therapeutics, Inc. CADL

$578.8M

Atea Pharmaceuticals, Inc. AVIR

$331.3M

Frequently Asked Questions

Is Neumora Therapeutics Inc profitable?

Yes, Neumora Therapeutics Inc (NMRA) reported a net income of $236.9M in fiscal year 2025.

What is Neumora Therapeutics Inc's EBITDA?

Neumora Therapeutics Inc (NMRA) had EBITDA of -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Neumora Therapeutics Inc have?

As of fiscal year 2025, Neumora Therapeutics Inc (NMRA) had $182.5M in cash and equivalents against $54.5M in long-term debt.

What is Neumora Therapeutics Inc's return on equity (ROE)?

Neumora Therapeutics Inc (NMRA) has a return on equity of 228.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Neumora Therapeutics Inc's operating cash flow?

Neumora Therapeutics Inc (NMRA) generated -$206.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Neumora Therapeutics Inc's total assets?

Neumora Therapeutics Inc (NMRA) had $191.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Neumora Therapeutics Inc spend on research and development?

Neumora Therapeutics Inc (NMRA) invested $176.1M in research and development during fiscal year 2025.

How many shares does Neumora Therapeutics Inc have outstanding?

Neumora Therapeutics Inc (NMRA) had 174M shares outstanding as of fiscal year 2025.

What is Neumora Therapeutics Inc's current ratio?

Neumora Therapeutics Inc (NMRA) had a current ratio of 5.87 as of fiscal year 2025, which is generally considered healthy.

What is Neumora Therapeutics Inc's debt-to-equity ratio?

Neumora Therapeutics Inc (NMRA) had a debt-to-equity ratio of 0.53 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Neumora Therapeutics Inc's return on assets (ROA)?

Neumora Therapeutics Inc (NMRA) had a return on assets of 124.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Neumora Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Neumora Therapeutics Inc (NMRA) had $182.5M in cash against an annual operating cash burn of $206.4M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Neumora Therapeutics Inc's Piotroski F-Score?

Neumora Therapeutics Inc (NMRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Neumora Therapeutics Inc's earnings high quality?

Neumora Therapeutics Inc (NMRA) has an earnings quality ratio of -0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Neumora Therapeutics Inc cover its interest payments?

Neumora Therapeutics Inc (NMRA) has an interest coverage ratio of -120.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Neumora Therapeutics Inc?

Neumora Therapeutics Inc (NMRA) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.